FindTrial
Sign In

Endocrinological evaluation of dawn phenomenon in diabetic patients and comparison of insulin glargine biosimillar (Insulin Glargine BS milliopen "Lilly") and glargine U-300 (Lantus XR)

Endocrinological evaluation of dawn phenomenon in diabetic patients and comparison of insulin glargine biosimillar (Insulin Glargine BS milliopen "Lilly") and glargine U-300 (Lantus XR) - Endocrinological evaluation of dawn phenomenon in diabetic patients and comparison of insulin glargine biosimillar (Insulin Glargine BS milliopen "Lilly") and glargine U-300 (Lantus XR)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000045464
Enrollment
50
Registered
2021-09-13
Start date
2018-07-31
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes

Interventions

Glargine XR Glargine

Sponsors

Chigasaki Municipal Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with type 1 and type 2 diabetes who have agreed to the purpose and content of this study and have voluntarily agreed to the document.

Exclusion criteria

Exclusion criteria: Patients with adrenal and pituitary diseases, patients who are chronically administered steroids, patients with cancer and patients with gestational diabetes.

Design outcomes

Primary

MeasureTime frame
Mean blood glucose and standard deviation of Flash Glucose Monitoring and Average and standard deviation of blood glucose levels and at 3:00 am and 7:00 am.—

Countries

Japan

Contacts

Public Contactmasanori hasebe

Chigasaki Municipal Hospital Metabolism internal secretion internal medicine

t186059g@yokohama-cu.ac.jp0467-52-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026